Relievant Medsystems Archives - Medical Design Sourcing

Boston Scientific closes Relievant Medsystems acquisition

The Intracept procedure. [Image from Relievant Medsystems]Boston Scientific (NYSE: BSX) + announced today that it completed its previously announced acquisition of Relievant Medsystems.

In September, Boston Scientific announced plans to acquire Relievant for an upfront cash payment of $850 million. Additional payments are contingent on sales performance over the next three years. Minneapolis-based Relievant developed and commercialized the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, same-day, outpatient procedure treats chronic vertebrogenic low back pain.

The procedure utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform. Boston Scientific says the Intracept system adds to its chronic pain portfolio.

Relievant rec…

Relievant Medsystems unveils Intracept simulation training program

The Intracept procedure. [Image from Relievant Medsystems]Relievant Medsystems announced today that it released its Intracept simulator system, a training platform for the Intracept procedure.

Further progress for Relievant and Intracept follows Tuesday’s major news of an agreement for Boston Scientific to acquire the company. Boston Scientific officials went into further detail on their expectations for the Relievant deal at the company’s Investor Day yesterday.

Minneapolis-based Relievant develops the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, same-day, outpatient procedure treats chronic vertebrogenic low back pain. Intracept utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.

Relievant based its simulator system for Intracept on Medabilit…

Boston Scientific to acquire nerve ablation tech developer Relievant Medsystems for $850M

The Intracept procedure. [Image from Relievant Medsystems]Boston Scientific (NYSE: BSX) + announced today that it entered into a definitive agreement to acquire Relievant Medsystems.

The transaction includes an upfront cash payment of $850 million. Additional payments are contingent on sales performance over the next three years.

Minneapolis-based Relievant developed and commercialized the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, same-day, outpatient procedure treats chronic vertebrogenic low back pain.

The procedure utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.

″We anticipate this novel, clinically-backed technology can support our category leadership strategy while expanding access to care for i…

4-year data backs Relievant Medsystems’ Intracept ablation procedure

The Intracept procedure. [Image from Relievant Medsystems]Relievant Medsystems announced four-year pooled data from two prospective clinical trials that support the use of its Intracept procedure.

Intracept — a minimally invasive, FDA-cleared, same-day, outpatient procedure — treats chronic vertebrogenic low back pain. The procedure utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.

Data from the study further demonstrated the safety, effectiveness and long-term durability of Intracept. The company just last month reported positive three-year data for the ablation procedure.

Minneapolis-based Relievant saw its study’s abstract named one of the “Top Abstracts” at the American Society of Pain & Neuroscience (ASPN) Annual Conference in Miami. Lead author Dr. Jad Khalil presented the study&#…

Relievant Medsystems unveils new tools for its ablation system

The Intracept procedure. [Image from Relievant Medsystems]Relievant Medsystems announced today that it launched its next-generation access instruments for the Intracept procedure.

Intracept, a minimally invasive, FDA-cleared, same-day, outpatient procedure, treats chronic vertebrogenic low back pain. It uses targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve it from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.

Minneapolis-based Relievant said in a news release that its new instruments offer more predictable and precise BVN targeting during Intracept. President and CEO Tyler Binney said the launch highlights the company’s commitment to continued innovation.

“Today, we are pleased to announce the launch of several new instruments offering greater control, precision, and ease of use during the procedure,” said Binney. “These next-generation Intracept …

Relievant Medsystems reports positive data for nerve ablation procedure

The Intracept procedure. [Image from Relievant Medsystems]Relievant Medsystems announced today that three-year data from two clinical trials further validate its Intracept procedure.

Intracept, a minimally invasive, FDA-cleared, same-day, outpatient procedure, treats chronic vertebrogenic low back pain. It uses targeted radiofrequency energy to ablate the basivertebral nerve (BVN), stopping it from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.

Minneapolis-based Relievant’s three-year pooled results validated the safety, effectiveness and long-term durability of Intracept. The company published the study results in Interventional Pain Medicine. Those results proved consistent with previously published long-term results measuring Intracept outcomes at five years.

The results included 95 patients successfully treated with Intracept across 22 study sites. Patients achieved statistically significant, clinica…

Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement efforts

Relievant Medsystems announced today that two new Category I Current Procedural Terminology (CPT) codes are now in effect for Intracept.

Minneapolis-based Relievant designed its Intracept device and procedure for the treatment of chronic low back pain (CLBP) from degenerative disc disease with Modic changes.

The new CPT codes — which went into effect as of Jan. 1, 2022 — are 64628 for the thermal destruction of the intraosseous basivertebral nerve, including all imaging guidance; first two vertebral bodies lumbar or sacral and 64629 for the thermal destruction of the intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral.

Relievant said in a news release that the codes follow the designation of a new ICD-10 diagnosis code specifically for vertebrogenic low back pain (M54.51) from the CDC, which went into effect in 2021.

“The Intracept procedure is a significant breakthrough in the treatme…